About

Founded

2014

Headquarters

Foster City, California

Industry

Biotech

Company Description

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community.

Quick Links

Website Jobs

Funding

Total Raised

$54.8 million

Valuation

Undisclosed

Significant Investors

Builders VC, Eleven Two Capital, First Round Capital, Founders Fund, Fuel Capital, Lightspeed Venture Partners, Upside Partnership, Y Combinator, B Capital Group, LifeForce Capital, Industry Ventures

Company Traction

Notable’s predictive precision medicine platform identifies responders with 92% accuracy in a study conducted at Stanford in 2020.

As of May 2023, NBL-001, a molecule in Notable’s pipeline, is at phase 1 for acute myeloid leukemia (AML) indication, preclinical for pediatric leukemia indication, and preclinical for solid tumors indication.

As of May 2023, Fosciclopirox, a molecule in Notable’s pipeline, is pre-clinical for AML indication.

Leadership Team

Thomas A. Bock, MD, MBA: CEO at Notable. Former Founder & CEO of HeritX.

Joseph Wagner: Chief Scientific Officer at Notable. Former Executive Director at the University of California Drug Discovery Consortium.

Matthew De Silva: Founder & Executive Chairman of Notable. COO at Pathos.

Connor Warnock: Director of Engineering at Notable. Former Lead Software Engineer at Townsquared.

Chris Leonardi: Head of Commercial, Partnerships & Alliances at Notable. Former VP of Business Development and Operations at InTeleLabs.

Press

Fierce Biotech (February 23, 2023): After a tough year, VBL merges with Notable Labs

Fierce Biotech (January 22, 2020): Notable Labs launches rolling blood cancer trial to test its AI system

VentureBeat (July 16, 2019): Notable raises $40 million to personalize cancer drug regimens

Notable Labs